Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trialAndrea Sartore‐Bianchi, Salvatore Siena, Sara Lonardi et al.|The Lancet Oncology|2016Cited by 1k
The genomic landscape of response to EGFR blockade in colorectal cancerAndrea Bertotti, Victor E. Velculescu, Eniko Papp et al.|Nature|2015Cited by 495